Trial of Tremelimumab in Patients With Previously Treated Metastatic Urothelial Cancer
Status:
Recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
This is a phase II trial designed to estimate the activity of single agent tremelimumab in
subjects with metastatic urothelial cancer with disease progression despite prior treatment
with PD-1/PD-L1 blockade. The primary endpoint is objective response rate and the study will
employ a Simon's 2-stage design.